Walnut Level Capital LLC grew its position in The Chemours Company (NYSE:CC - Free Report) by 60.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,000 shares of the specialty chemicals company's stock after buying an additional 30,000 shares during the quarter. Chemours accounts for approximately 0.5% of Walnut Level Capital LLC's holdings, making the stock its 28th biggest holding. Walnut Level Capital LLC owned 0.05% of Chemours worth $1,352,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC grew its stake in Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock valued at $26,000 after acquiring an additional 765 shares during the last quarter. Truvestments Capital LLC purchased a new stake in shares of Chemours in the third quarter valued at about $35,000. Brooklyn Investment Group acquired a new stake in shares of Chemours in the third quarter valued at approximately $37,000. KBC Group NV increased its stake in shares of Chemours by 38.2% during the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after purchasing an additional 1,708 shares in the last quarter. Finally, Quest Partners LLC raised its position in shares of Chemours by 7,206.4% during the 3rd quarter. Quest Partners LLC now owns 7,964 shares of the specialty chemicals company's stock worth $162,000 after purchasing an additional 7,855 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the company. The Goldman Sachs Group lowered their target price on Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. BMO Capital Markets decreased their price objective on Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 19th. Barclays cut their target price on shares of Chemours from $23.00 to $19.00 and set an "equal weight" rating for the company in a research note on Monday, February 24th. Mizuho raised Chemours from a "neutral" rating to an "outperform" rating and set a $19.00 price target on the stock in a research note on Thursday. Finally, Truist Financial initiated coverage on Chemours in a research report on Tuesday, January 28th. They issued a "buy" rating and a $27.00 price objective for the company. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $22.89.
View Our Latest Analysis on Chemours
Chemours Stock Down 4.0 %
CC traded down $0.57 during trading hours on Friday, reaching $13.73. 2,347,561 shares of the stock traded hands, compared to its average volume of 1,727,933. The Chemours Company has a fifty-two week low of $13.09 and a fifty-two week high of $29.21. The company has a market cap of $2.05 billion, a price-to-earnings ratio of 24.08 and a beta of 2.00. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The firm's fifty day simple moving average is $16.41 and its two-hundred day simple moving average is $18.19.
Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. As a group, analysts forecast that The Chemours Company will post 2.03 earnings per share for the current fiscal year.
Chemours Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were issued a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 annualized dividend and a yield of 7.29%. Chemours's dividend payout ratio is presently 175.44%.
Chemours Profile
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Articles
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
